 Tissue Plasminogen Activator
"Tissue Plasminogen Activator" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases.
| Descriptor ID |
D010959
|
| MeSH Number(s) |
D08.811.277.656.300.760.875 D08.811.277.656.959.350.875 D12.776.124.125.662.768 D23.119.970
|
| Concept/Terms |
Tissue Plasminogen Activator- Tissue Plasminogen Activator
- Plasminogen Activator, Tissue
- Tissue Activator D-44
- Tissue Activator D 44
- Tisokinase
- Tissue-Type Plasminogen Activator
- Tissue Type Plasminogen Activator
- TTPA
- T-Plasminogen Activator
- T Plasminogen Activator
- Alteplase
- Plasminogen Activator, Tissue-Type
- Plasminogen Activator, Tissue Type
Actilyse- Actilyse
- Lysatec rt-PA
- Lysatec rt PA
- Lysatec rtPA
|
Below are MeSH descriptors whose meaning is more general than "Tissue Plasminogen Activator".
Below are MeSH descriptors whose meaning is more specific than "Tissue Plasminogen Activator".
This graph shows the total number of publications written about "Tissue Plasminogen Activator" by people in this website by year, and whether "Tissue Plasminogen Activator" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 1997 | 3 | 2 | 5 | | 1998 | 2 | 2 | 4 | | 2002 | 2 | 1 | 3 | | 2003 | 4 | 1 | 5 | | 2004 | 1 | 0 | 1 | | 2005 | 5 | 1 | 6 | | 2006 | 4 | 0 | 4 | | 2007 | 1 | 0 | 1 | | 2008 | 1 | 0 | 1 | | 2009 | 5 | 1 | 6 | | 2011 | 4 | 3 | 7 | | 2012 | 3 | 0 | 3 | | 2013 | 4 | 2 | 6 | | 2014 | 6 | 2 | 8 | | 2015 | 11 | 2 | 13 | | 2016 | 1 | 0 | 1 | | 2017 | 8 | 2 | 10 | | 2018 | 2 | 2 | 4 | | 2019 | 2 | 2 | 4 | | 2020 | 6 | 1 | 7 | | 2021 | 6 | 2 | 8 | | 2022 | 3 | 5 | 8 | | 2023 | 1 | 12 | 13 | | 2024 | 1 | 4 | 5 | | 2025 | 3 | 2 | 5 | | 2026 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Tissue Plasminogen Activator" by people in Profiles.
-
Valenti WB, Ruzzene ST, Berry AR, Orozco-Fersiva NC, Stone MF, Gilmore EC, Holzer JP, Mollaian JS, Greiner JJ, Garcia VP, DeSouza CA. Effect of 17ß-estradiol on brain microvascular endothelial cell oxidative stress, apoptotic susceptibility, and fibrinolytic capacity. J Appl Physiol (1985). 2026 Jun 01; 140(6):1804-1812.
-
Massicotte S, Vatanpour S, Doolan C, Zhang J, Ganesh A, Choi PMC, Buck BH, Field TS, Yu AYX, Kleinig TJ, Muir KW, Campbell BCV, Molina CA, Appireddy R, Hill MD, Singh N, Coutts SB. Intracranial Hemorrhage Patterns and Outcomes in Minor Stroke: Analysis of the TEMPO-2 Trial. Stroke. 2026 Jun; 57(6):1526-1534.
-
Navi BB, Wang M, Yamal JM, Rajan SS, Czap AL, Parker SA, Nour M, Spokoyny I, Mir S, Fink ME, Willey JZ, Jones WJ, Grotta JC. Potential Missed Opportunities to Administer Intravenous Thrombolysis to Patients With Acute Ischemic Stroke. Stroke. 2026 Mar; 57(3):633-640.
-
Ruzzene ST, Berry AR, Garcia VP, Valenti WB, Izaias JE, Stockelman KA, Greiner JJ, Park AJ, Stauffer BL, DeSouza CA. Obesity-related elevation in circulating endothelial-derived extracellular microvesicles and endothelial fibrinolytic dysfunction. Am J Physiol Heart Circ Physiol. 2026 01 01; 330(1):H319-H326.
-
Gonsalves CF, Stortecky S, Horr S, Pappas O, Gandhi RT, Pereira K, Giri J, Khandhar SJ, Azene EM, Elmasri F, Lindquist J, Jaber WA. Evaluation of Catheter-Directed Thrombolysis Device Type and Dosing on Treatment Outcomes in Intermediate-Risk Pulmonary Embolism: A PEERLESS Randomized Controlled Trial Post Hoc Analysis. J Vasc Interv Radiol. 2026 01; 37(1):107866.
-
Moore PK, Hershberger DM, Barrett CD. Intrapleural Fibrinolytic Therapy: Past, Present, and Future. Chest. 2026 Feb; 169(2):360-370.
-
Moore PK, Moore EE, Garner R, Hansen K, Barrett CD, Sauaia A, Chandler J, Janssen WJ, Moore HB. Coagulation factor XIII: An unrecognized regulator of fibrinolytic phenotypes in trauma-A potential link to cysteine cathepsin degradation of plasminogen. J Trauma Acute Care Surg. 2026 02 01; 100(2):271-280.
-
Maginot ER, Gawargi FI, Moore EE, White CM, Volk GE, Moody TB, Sextro KS, Hiser D, Tierney JF, Sheppard OO, Evans CH, Cantrell E, Kamien AJ, Lamb GD, Matos M, Veatch J, Cloonan MR, Chandler JG, Moore HB, Moore PK, Sauaia A, Bernhardt IM, Yaffe MB, Bauman ZM, Henry R, Barrett CD. Plasminogen supplementation improves lysis of inflammatory retained traumatic hemothorax. J Trauma Acute Care Surg. 2026 01 01; 100(1):20-27.
-
Garcia VP, Stockelman KA, Levy MV, Fandl HK, Goulding A, Hijmans JG, Ruzzene ST, Berry AR, Greiner JJ, DeSouza CA. Microvesicles Derived from Nitric Oxide Synthase-Inhibited Endothelial Cells Promote Cell Dysfunction. J Vasc Res. 2025; 62(1):10-21.
-
Rajan SS, Yamal JM, Wang M, Saver JL, Jacob AP, Gonzales NR, Ifejika N, Parker SA, Ganey C, Gonzalez MO, Lairson DR, Bratina PL, Jones WJ, Mackey JS, Lerario MP, Navi BB, Alexandrov AW, Alexandrov A, Nour M, Spokoyny I, Bowry R, Czap AL, Grotta JC. A Prospective Multicenter Analysis of Mobile Stroke Unit Cost-Effectiveness. Ann Neurol. 2025 02; 97(2):209-221.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|